720 related articles for article (PubMed ID: 17433090)
1. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
[TBL] [Abstract][Full Text] [Related]
3. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
5. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
7. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
[TBL] [Abstract][Full Text] [Related]
8. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.
Massoumi H; Elsiesy H; Khaitova V; Peterson B; Norkus E; Grewal P; Liu L; Chang C; Bach N; Schiano TD
Transplantation; 2009 Sep; 88(5):729-35. PubMed ID: 19741473
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
[TBL] [Abstract][Full Text] [Related]
10. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
Al-Hamoudi W; Mohamed H; Abaalkhail F; Kamel Y; Al-Masri N; Allam N; Alqahtani S; Al-Sofayan M; Khalaf H; Al-Sebayel M; Al-Jedai A; Abdo A
Dig Dis Sci; 2011 Jun; 56(6):1848-52. PubMed ID: 21221800
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
15. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
Malone DC; Tran TT; Poordad FF
J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
19. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
Akhan SC; Kalender B; Ruzgar M
Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
[TBL] [Abstract][Full Text] [Related]
20. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
